121 related articles for article (PubMed ID: 28904384)
1. Targeting the vulnerability to NAD
Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
[TBL] [Abstract][Full Text] [Related]
2. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
3. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
[TBL] [Abstract][Full Text] [Related]
4. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
5. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Venkateshaiah SU; Khan S; Ling W; Bam R; Li X; van Rhee F; Usmani S; Barlogie B; Epstein J; Yaccoby S
Exp Hematol; 2013 Jun; 41(6):547-557.e2. PubMed ID: 23435312
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
Yin C; Jia S; Yang X; Wu L
Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
[TBL] [Abstract][Full Text] [Related]
7. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.
Velma GR; Krider IS; Alves ETM; Courey JM; Laham MS; Thatcher GRJ
J Med Chem; 2024 Apr; 67(8):5999-6026. PubMed ID: 38580317
[TBL] [Abstract][Full Text] [Related]
8. NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers.
Zhu X; Li Y; Liu H; Wang Y; Sun R; Jiang Z; Hou C; Hou X; Huang S; Zhang H; Wang H; Jiang B; Yang X; Xu B; Fan G
Cell Chem Biol; 2024 Jun; 31(6):1203-1218.e17. PubMed ID: 38906111
[TBL] [Abstract][Full Text] [Related]
9. Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway.
Shats I; Williams JG; Liu J; Makarov MV; Wu X; Lih FB; Deterding LJ; Lim C; Xu X; Randall TA; Lee E; Li W; Fan W; Li JL; Sokolsky M; Kabanov AV; Li L; Migaud ME; Locasale JW; Li X
Cell Metab; 2020 Mar; 31(3):564-579.e7. PubMed ID: 32130883
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Dual Function Agents That Exhibit Anticancer Activity via Catastrophic Nicotinamide Adenine Dinucleotide Depletion.
Fu Y; Huang Y; Zhou C; Li X; Dong G; Huang M; Ding J; Sheng C
J Med Chem; 2023 Dec; 66(24):16694-16703. PubMed ID: 38060985
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models.
McKay-Corkum GB; Collins VJ; Yeung C; Ito T; Issaq SH; Holland D; Vulikh K; Zhang Y; Lee U; Lei H; Mendoza A; Shern JF; Yohe ME; Yamamoto K; Wilson K; Ji J; Karim BO; Thomas CJ; Krishna MC; Neckers LM; Heske CM
Clin Cancer Res; 2023 Nov; 29(21):4479-4491. PubMed ID: 37616468
[TBL] [Abstract][Full Text] [Related]
12. Targeting NAD+ Metabolism: Preclinical Insights into Potential Cancer Therapy Strategies.
Mogol AN; Kaminsky AZ; Dutton DJ; Madak Erdogan Z
Endocrinology; 2024 Mar; 165(5):. PubMed ID: 38565429
[TBL] [Abstract][Full Text] [Related]
13. A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome.
Messana VG; Fascì A; Vitale N; Micillo M; Rovere M; Pesce NA; Martines C; Efremov DG; Vaisitti T; Deaglio S
Blood Adv; 2024 Apr; 8(8):1920-1933. PubMed ID: 38359376
[TBL] [Abstract][Full Text] [Related]
14. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia.
Eldfors S; Saad J; Ikonen N; Malani D; Vähä-Koskela M; Gjertsen BT; Kontro M; Porkka K; Heckman CA
Blood Adv; 2024 Apr; 8(7):1621-1633. PubMed ID: 38197948
[TBL] [Abstract][Full Text] [Related]
15. Advances in NAD-Lowering Agents for Cancer Treatment.
Ghanem MS; Monacelli F; Nencioni A
Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
[TBL] [Abstract][Full Text] [Related]
16. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.
Nomura M; Ohuchi M; Sakamoto Y; Kudo K; Yaku K; Soga T; Sugiura Y; Morita M; Hayashi K; Miyahara S; Sato T; Yamashita Y; Ito S; Kikuchi N; Sato I; Saito R; Yaegashi N; Fukuhara T; Yamada H; Shima H; Nakayama KI; Hirao A; Kawasaki K; Arai Y; Akamatsu S; Tanuma SI; Sato T; Nakagawa T; Tanuma N
Nat Commun; 2023 Dec; 14(1):8095. PubMed ID: 38092728
[TBL] [Abstract][Full Text] [Related]
17. Thiophenyl Derivatives of Nicotinamide Are Metabolized by the NAD Salvage Pathway into Unnatural NAD Derivatives That Inhibit IMPDH and Are Toxic to Peripheral Nerve Cancers.
Theodoropoulos PC; Guo HH; Wang W; Crossley E; Rivera Cancel G; Fang M; Nguyen T; Baniasadi H; Williams NS; Ready JM; De Brabander JK; Nijhawan D
ACS Chem Biol; 2024 Jun; 19(6):1339-1350. PubMed ID: 38829020
[TBL] [Abstract][Full Text] [Related]
18. Combined Targeting of NAD Biosynthesis and the NAD-dependent Transcription Factor C-terminal Binding Protein as a Promising Novel Therapy for Pancreatic Cancer.
Dcona MM; Chougoni KK; Dcona DT; West JL; Singh SJ; Ellis KC; Grossman SR
Cancer Res Commun; 2023 Oct; 3(10):2003-2013. PubMed ID: 37707363
[TBL] [Abstract][Full Text] [Related]
19. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response.
Xu S; Ma B; Jian Y; Yao C; Wang Z; Fan Y; Ma J; Chen Y; Feng X; An J; Chen J; Wang K; Xie H; Gao Y; Li L
EBioMedicine; 2024 Jun; 104():105162. PubMed ID: 38810561
[TBL] [Abstract][Full Text] [Related]
20. The impact of MCCK1, an inhibitor of IKBKE kinase, on acute B lymphocyte leukemia cells.
Wen S; Zhao P; Chen S; Deng B; Fang Q; Wang J
Math Biosci Eng; 2024 Mar; 21(4):5164-5180. PubMed ID: 38872531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
